Notification of cessation of securities - TLX

Oct 4, 2026 at 5:23 PM EDT · Issued by Telix Pharmaceuticals Limited via ASX

Filed with ASX · Oct 4, 2026 at 5:23 PM EDT · 6 pages · English

On 6ix: 6ix.com/news/notification-of-cessation-of-securities-tlx

Release

Appendix 3H - Notification of cessation of securitiesAppendix 3H - Notification of cessation of securities1 / 6Announcement SummaryEntity nameTELIX PHARMACEUTICALS LIMITEDAnnouncement TypeNew announcementDate of this announcementMonday October 05, 2026Details of +securities that have ceasedASX...

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

Notification regarding unquoted securities - TLXOct 4
Application for quotation of securities - TLXOct 4
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer ImagingSep 29
FDA Fast Track for BiPASS Pre Biopsy Prostate ImagingSep 29
Change in substantial holdingSep 25

Later from Telix Pharmaceuticals

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)Oct 6
Telix to Host Capital Markets Day in Melbourne on November 4, 2026Oct 9
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANMOct 14
Telix Reports Third Quarter 2026 Financial PerformanceOct 20
Appendix 3Y Change in Director Interest - D GillOct 25

All Telix Pharmaceuticals news releases

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals